Active Ingredient: Eptinezumab
Dosage Form: Injection
Strength: 24 mg per 1.2 mL
Quantity: Single dose vial (1.2 mL)

 

Medical Uses

• Migraine Prevention:
  • Primary Use: Ngenla is indicated for the prevention of episodic and chronic migraines in adults. It works by binding to and blocking CGRP, a molecule involved in the initiation and maintenance of migraines.
  • Administration: The recommended dose is a single 24 mg injection administered intravenously every 3 months. This schedule helps to reduce the frequency and severity of migraine attacks.

 

Usage in Sports and Bodybuilding

Why Athletes Might Use Ngenla:

• Migraine Management: Athletes who suffer from frequent migraines may use Ngenla to manage their condition and improve their overall quality of life. Reducing the frequency and intensity of migraines can help maintain consistent training and performance levels.

How Athletes Use Ngenla:

• Dosage: For migraine prevention, a single dose of 24 mg is administered every 3 months. This regimen is designed to keep CGRP levels low, reducing migraine frequency.
• Administration: The injection is given intravenously by a healthcare provider. Athletes should consult with a healthcare professional to ensure proper administration and to monitor for potential side effects.

 

Storage Conditions:

• Temperature: Store in a refrigerator at 2°C to 8°C (36°F to 46°F).
• Light: Protect from light; keep in the original carton to shield from light.
• Moisture: Store in a dry place; do not freeze.
• Preparation: Do not use if the solution is cloudy or contains particles.
• Expiry: Use before the expiration date on the packaging. Discard unused portions.

 

Precautions and Side Effects

Potential Side Effects:

• Common Reactions: Some common side effects include injection site reactions (such as pain, redness, or swelling), and occasional flu-like symptoms.
• Serious Reactions: Rare but serious side effects may include hypersensitivity reactions or severe allergic responses.

 

Medical Warnings:

• Pre-existing Conditions: Individuals with a history of severe allergies or hypersensitivity to eptinezumab or any of its components should avoid using this medication.
• Pregnancy and Nursing: The safety of Ngenla during pregnancy or lactation has not been well studied. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult a healthcare provider before use.

Consultation:

• Medical Supervision: Always use Ngenla under the supervision of a healthcare provider. Regular follow-ups are necessary to monitor the effectiveness of the treatment and manage any potential side effects.

 

Conclusion

Ngenla 24 mg/1.2 mL is a targeted therapy for the prevention of migraines, providing relief by inhibiting CGRP. It is administered intravenously every 3 months and is effective in reducing the frequency and severity of migraine attacks.

 

For further inquiries or to schedule a consultation, please contact us at info@staminapharma.com.